ATE260338T1 - Hefestämme und modifizierte albumine - Google Patents

Hefestämme und modifizierte albumine

Info

Publication number
ATE260338T1
ATE260338T1 AT95909880T AT95909880T ATE260338T1 AT E260338 T1 ATE260338 T1 AT E260338T1 AT 95909880 T AT95909880 T AT 95909880T AT 95909880 T AT95909880 T AT 95909880T AT E260338 T1 ATE260338 T1 AT E260338T1
Authority
AT
Austria
Prior art keywords
pct
albumin
yeast strains
yeast
yap3p
Prior art date
Application number
AT95909880T
Other languages
English (en)
Inventor
Sean Martin Kerry-Williams
Sarah Catherine Gilbert
Original Assignee
Delta Biotechnology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Delta Biotechnology Ltd filed Critical Delta Biotechnology Ltd
Application granted granted Critical
Publication of ATE260338T1 publication Critical patent/ATE260338T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/58—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from fungi
    • C12N9/60—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from fungi from yeast

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT95909880T 1994-03-05 1995-03-01 Hefestämme und modifizierte albumine ATE260338T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9404270A GB9404270D0 (en) 1994-03-05 1994-03-05 Yeast strains and modified albumins
PCT/GB1995/000434 WO1995023857A1 (en) 1994-03-05 1995-03-01 Yeast strains and modified albumins

Publications (1)

Publication Number Publication Date
ATE260338T1 true ATE260338T1 (de) 2004-03-15

Family

ID=10751353

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95909880T ATE260338T1 (de) 1994-03-05 1995-03-01 Hefestämme und modifizierte albumine

Country Status (13)

Country Link
US (1) US5965386A (de)
EP (1) EP0749478B1 (de)
JP (1) JP3795073B2 (de)
KR (1) KR100372514B1 (de)
AT (1) ATE260338T1 (de)
AU (1) AU683728B2 (de)
CA (1) CA2183241C (de)
DE (1) DE69532603T2 (de)
DK (1) DK0749478T3 (de)
ES (1) ES2216007T3 (de)
GB (2) GB9404270D0 (de)
PT (1) PT749478E (de)
WO (1) WO1995023857A1 (de)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2686899B1 (fr) * 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
GB9526733D0 (en) 1995-12-30 1996-02-28 Delta Biotechnology Ltd Fusion proteins
AU3255397A (en) * 1996-07-05 1998-02-02 Novo Nordisk A/S Method for the production of precursors of insulin, precursors of insulin analogues, and insulin like peptides
AU3255497A (en) * 1996-07-05 1998-02-02 Novo Nordisk A/S Method for the production of polypeptides
US6110703A (en) * 1996-07-05 2000-08-29 Novo Nordisk A/S Method for the production of polypeptides
US6274305B1 (en) 1996-12-19 2001-08-14 Tufts University Inhibiting proliferation of cancer cells
US6265186B1 (en) 1997-04-11 2001-07-24 Dsm N.V. Yeast cells comprising at least two copies of a desired gene integrated into the chromosomal genome at more than one non-ribosomal RNA encoding domain, particularly with Kluyveromyces
WO1999037758A2 (en) * 1998-01-27 1999-07-29 The Board Of Regents Of The University And Community College System Of Nevada On Behalf Of The University Of Nevada-Reno Expression of proteolytically-sensitive peptides
GB9902000D0 (en) 1999-01-30 1999-03-17 Delta Biotechnology Ltd Process
US6946134B1 (en) 2000-04-12 2005-09-20 Human Genome Sciences, Inc. Albumin fusion proteins
EP1803730A1 (de) 2000-04-12 2007-07-04 Human Genome Sciences, Inc. Albuminfusionsproteine
WO2002022685A2 (en) * 2000-09-11 2002-03-21 Kufe Donald W Muc1 extracellular domain and cancer treatment compositions and methods derived therefrom
EP1958642A1 (de) * 2000-12-22 2008-08-20 Dana-Farber Cancer Institute Regulierung des Zellwachstums durch MUC1
US20050054051A1 (en) * 2001-04-12 2005-03-10 Human Genome Sciences, Inc. Albumin fusion proteins
US7507413B2 (en) * 2001-04-12 2009-03-24 Human Genome Sciences, Inc. Albumin fusion proteins
JP2003047471A (ja) * 2001-08-01 2003-02-18 Kirin Brewery Co Ltd 異種タンパク質の分泌生産に優れた改変酵母およびその酵母を用いた異種タンパク質の製造法
US7176278B2 (en) 2001-08-30 2007-02-13 Biorexis Technology, Inc. Modified transferrin fusion proteins
CA2484556A1 (en) 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin fusion proteins
US20080194481A1 (en) 2001-12-21 2008-08-14 Human Genome Sciences, Inc. Albumin Fusion Proteins
EP1997829A1 (de) 2001-12-21 2008-12-03 Human Genome Sciences, Inc. Albumin Fusionsproteine
JP2005538932A (ja) 2002-02-07 2005-12-22 アベンティス、ベーリング、ゲゼルシャフト、ミット、ベシュレンクテル、ハフツング アルブミン融合クニッツドメインペプチド
US7879365B2 (en) * 2002-02-07 2011-02-01 The Trustees Of Columbia University In The City Of New York Zinc salt compositions for the prevention of dermal and mucosal irritation
US7972809B2 (en) 2002-04-26 2011-07-05 National Institute Of Advanced Industrial Science & Technology Methylotrophic yeast producing mammalian type sugar chain
ATE480624T1 (de) * 2002-06-29 2010-09-15 Korea Res Inst Of Bioscience Yapsin-mangelmutantenstamm von hansenula polymorpha sowie verfahren zur herstellung rekombinanter proteine damit
CA2513213C (en) 2003-01-22 2013-07-30 Human Genome Sciences, Inc. Albumin fusion proteins
WO2004092339A2 (en) * 2003-04-11 2004-10-28 Ilex Products, Inc. Modulation of muc1 mediated signal transduction
US8129506B2 (en) * 2003-10-24 2012-03-06 Genzyme Corporation Modulation of the interaction of MUC1 with MUC1 ligands
GB0329681D0 (en) 2003-12-23 2004-01-28 Delta Biotechnology Ltd Gene expression technique
GB0329722D0 (en) 2003-12-23 2004-01-28 Delta Biotechnology Ltd Modified plasmid and use thereof
EP1708734A4 (de) * 2004-01-07 2009-06-17 Trimeris Inc Von hiv gp41 hr2 abgeleitete peptide und deren verwendung in der therapie zur hemmung der übertragung des humanen immundefizienzvirus
CA2556729A1 (en) * 2004-02-23 2005-09-09 Genzyme Corporation Muc1 antagonist enhancement of death receptor ligand-induced apoptosis
CA2581423A1 (en) 2004-09-23 2006-03-30 Vasgene Therapeutics, Inc. Polipeptide compounds for inhibiting angiogenesis and tumor growth
AU2005317828A1 (en) 2004-12-23 2006-06-29 Novozymes Delta Limited Gene expression technique
AU2006344395B2 (en) 2005-10-13 2013-05-02 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive diseases
EP1989220B1 (de) * 2006-02-02 2011-12-14 Trimeris, Inc. Hiv-fusionshemmerpeptide mit verbesserten biologischen eigenschaften
KR101193722B1 (ko) 2006-07-24 2013-01-11 바이오렉시스 파마슈티칼 코포레이션 엑센딘 융합 단백질
EP2054437A2 (de) * 2006-08-07 2009-05-06 Teva Biopharmaceuticals USA, Inc. Albumin-insulin-fusionsproteine
CN106008699A (zh) 2006-09-08 2016-10-12 Ambrx公司 经修饰的人类血浆多肽或Fc骨架和其用途
US7871784B2 (en) * 2007-02-02 2011-01-18 Dana-Farber Cancer Institute, Inc. Methods and compositions relating to the regulation of apoptosis by MUC1 and BH3-containing proapoptotic proteins
US7972870B2 (en) 2007-02-02 2011-07-05 Dana-Farber Cancer Institute, Inc. Methods and compositions relating to the regulation of MUC1 by HSF1 and STAT3
MX2009010689A (es) * 2007-04-03 2009-12-14 Trimeris Inc Formulaciones novedosas para el suministro de agentes terapeuticos de peptidos antivirales.
CN101835801B (zh) 2007-08-08 2014-09-10 诺维信生物制药丹麦公司 转铁蛋白变体和偶联物
US20100261876A1 (en) * 2007-09-25 2010-10-14 Bray Brian L Novel methods of synthesis for therapeutic antiviral peptides
WO2010089385A1 (en) 2009-02-06 2010-08-12 Novozymes Biopharma Dk A/S Purification process
JP5936112B2 (ja) 2009-02-11 2016-06-15 アルブミディクス アクティーゼルスカブ アルブミン変異体及び複合体
BR112012009450A2 (pt) 2009-10-30 2017-05-23 Novozymes Biopharma Dk As variantes de albumina
EP2504355B1 (de) 2009-11-25 2015-07-22 Novo Nordisk A/S Verfahren zur herstellung von polypeptiden
ES2678144T3 (es) 2010-02-16 2018-08-09 Medimmune, Llc Composiciones relacionadas con SAH y métodos de uso
EP2554656B1 (de) * 2010-03-26 2018-05-16 Asahi Group Holdings, Ltd. Verfahren zur kultivierung von hefe
US10233228B2 (en) 2010-04-09 2019-03-19 Albumedix Ltd Albumin derivatives and variants
US9045564B2 (en) 2011-02-15 2015-06-02 Medimmune, Llc HSA-related compositions and methods of use
JP2014510518A (ja) * 2011-02-15 2014-05-01 メディミューン，エルエルシー Ｈｓａ関連組成物および使用方法
CN103732628B (zh) 2011-03-03 2017-06-23 酵活有限公司 多价杂多聚体骨架设计和构建体
CA2830660A1 (en) 2011-05-05 2012-11-08 Novozymes Biopharma Dk A/S Albumin variants
HK1200842A1 (en) 2011-11-18 2015-08-14 Albumedix Ltd Proteins with improved half-life and other properties
CN104736559B (zh) 2012-03-16 2022-04-08 阿尔布梅迪克斯医疗有限公司 白蛋白变体
CA2878640C (en) 2012-07-13 2023-10-24 Zymeworks Inc. Multivalent heteromultimer scaffold design and constructs
CN105452290A (zh) 2012-11-08 2016-03-30 诺维信生物制药丹麦公司 白蛋白变体
RU2663587C2 (ru) * 2013-03-06 2018-08-07 ГЛЭКСОСМИТКЛАЙН ЭлЭлСи Клетки-хозяева и способы использования
WO2014165093A2 (en) 2013-03-13 2014-10-09 Bristol-Myers Squibb Company Fibronectin based scaffold domains linked to serum albumin or a moiety binding thereto
US20160168198A1 (en) * 2013-07-01 2016-06-16 Biocon Limited Signal sequence for protein expression in pichia pastoris
MX2018001825A (es) 2015-08-20 2018-05-07 Albumedix As Variantes y conjugados de albumina.
US12497441B2 (en) 2018-10-29 2025-12-16 Spin Therapeutics, Llc Compositions and methods for alpha-1-antitrypsin disorders
US12161777B2 (en) 2020-07-02 2024-12-10 Davol Inc. Flowable hemostatic suspension
US11739166B2 (en) 2020-07-02 2023-08-29 Davol Inc. Reactive polysaccharide-based hemostatic agent
MX2023007767A (es) 2020-12-28 2023-07-07 Davol Inc Materiales hemostaticos secos en polvo reactivos que comprenden una proteina y un agente de entrelazado a base de polietilenglicol modificado multifuncional.
CN114957448B (zh) * 2022-06-08 2023-08-25 中国农业科学院生物技术研究所 一种高效表达α-乳白蛋白的酵母菌株和α-乳白蛋白及其应用
CN118580980B (zh) * 2024-08-07 2024-10-15 通化安睿特生物制药股份有限公司 一种用于制备重组人白蛋白的重组工程菌及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01240191A (ja) * 1988-02-16 1989-09-25 Green Cross Corp:The 酵母で機能する新規シグナルペプチドおよびこれを用いた異種蛋白質の分泌発現
DK0548012T3 (da) * 1991-12-16 1998-04-14 Ciba Geigy Ag Endoplasmatisk reticulum-placeret rekombinant dibasisk endoprotease samt dens anvendelse
US5440018A (en) * 1992-05-20 1995-08-08 The Green Cross Corporation Recombinant human serum albumin, process for producing the same and pharmaceutical preparation containing the same

Also Published As

Publication number Publication date
WO1995023857A1 (en) 1995-09-08
DK0749478T3 (da) 2004-06-28
PT749478E (pt) 2004-07-30
CA2183241C (en) 2002-05-21
DE69532603D1 (de) 2004-04-01
AU1818395A (en) 1995-09-18
ES2216007T3 (es) 2004-10-16
EP0749478A1 (de) 1996-12-27
US5965386A (en) 1999-10-12
EP0749478B1 (de) 2004-02-25
DE69532603T2 (de) 2005-01-05
JPH09509581A (ja) 1997-09-30
AU683728B2 (en) 1997-11-20
GB9404270D0 (en) 1994-04-20
KR100372514B1 (ko) 2004-04-30
GB2301365A (en) 1996-12-04
JP3795073B2 (ja) 2006-07-12
GB9616724D0 (en) 1996-09-25
GB2301365B (en) 1997-07-30
CA2183241A1 (en) 1995-09-08

Similar Documents

Publication Publication Date Title
ATE260338T1 (de) Hefestämme und modifizierte albumine
GB2302329B (en) Yeast strains
WO1996017924A3 (en) Novel hedgehog-derived polypeptides
KR970702917A (ko) Lag-3의 가용성 폴리펩타이드 절편 및 생산 방법, 치료 조성물, 항-이디오타입 항체
DK0423302T3 (da) Anvendelse af hidtil ukendte DNA-fragmenter som kodende sekvens for et signalpeptid til sekretion af modne proteiner i rekombinant gær, ekspressionskassetter, transformeret gær og tilsvarende fremgangsmåde til fremstilling af proteiner
ATE112687T1 (de) Mutanten des hiv-1 hüllproteins mit fehlenden hypervariabelen domänen.
ATE106943T1 (de) Variante cd44-oberflächenproteine, diese kodierende dna-sequenzen, antikörper gegen diese proteine sowie ihre verwendung in der diagnostik und therapie.
DE69410254D1 (de) Behandlung von mycobakteriellen erkrankungen durch verabreichung von bakrerientötende, durchlässigkeitserhöhende proteinfragmente
ATE226436T1 (de) Neue verwendung von dexmedetomidin
BG103016A (en) Polypeptides capable of forming antigen-binding structures of specificity to rhesus d antigens, their encoding dna and method for their prparation and application
ATE233314T1 (de) Eine sekretionssequenz für die herstellung von heterologen proteinen in hefe
ATE360695T1 (de) Cortistatin: neuropeptide, zusammensetzungen und methoden
ATE183397T1 (de) Behandlung präkanzeröser läsionen durch muramylpeptide
ATE129228T1 (de) Neue 15,16-seco-19-nor-progestine.
DK0547200T3 (da) Rekombinante antistoffer på overfladen af E. coli
FI101631B1 (fi) Cliocladium catenulatum -sienikannat kasvitautien biologiseen torjuntaan
DE69431603D1 (de) Oligopeptide hergeleitet von fragmenten des c-reaktiven proteins
NO951926L (no) Fremgangsmåte for fremstilling av rekombinant aprotinin og rekombinante aprotininvarianter med naturlig N-terminalsekvens
ATE123056T1 (de) Ancrod-proteine, ihre herstellung und verwendung.
DE59611353D1 (de) Transketolase-verwandtes protein
FR2678636B1 (de)
ATE161576T1 (de) Proteasen aus dendryphiella
DE59407666D1 (de) VERFAHREN ZUR HERSTELLUNG VON 8-g(a),12-OXIDO-13,14,15,16-TETRANORLABDAN
WO2001079439A3 (fr) Nouveau polypeptide, proteine humaine de reception cannabinoide 19, et un polynucleotide codant pour ce polypeptide
WO2001075051A3 (fr) Nouveau polypeptide, proteine humaine 17 stag3 (antigene stromal), et polynucleotide codant pour ce polypeptide

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0749478

Country of ref document: EP

EEFA Change of the company name
EEIH Change in the person of patent owner